Achilles Therapeutics plc

Cancer care has made remarkable strides in recent years, and at the heart of some of the most promising new technologies are clonal neoantigens, mutations that occur early in the development of cancer and are present in all subsequent cancer cells. Learn more about these exciting targets and how they are used in the development of personalized cancer vaccines in Citeline Commercial In Vivo, in an article from our CEO Iraj Ali.   Read more here: https://lnkd.in/eAFJd3hB   #Oncology #Preciision #CancerResearch #Neoantigens #Clonals

Our Head of Quality Control Rebecca Moore will be speaking at the 3rd Annual Cell Therapy Analytical Development Summit in London.   Rebecca’s presentation, titled ‘Advancing Analytical Methods in Clinical Stages with Commercial Considerations’ is at 12.45pm BST on 5th September.   Please reach out if you’d like to connect with Rebecca.   #Presentation #Oncology #Neoantigens #Clonals

Today we reported our second quarter 2024 financial results and recent business updates.   Our highlights from Q2 include: ·      A research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines ·      An interim Phase I/IIa update on the use of cNeT in advanced NSCLC and melanoma, with the first three enhanced host conditioning patients showing improved cNeT persistence and engraftment ·      A strong cash position of $95.1 million supporting operations through 2025   Read the full press release here: https://lnkd.in/eN82rXZP   #Earnings #Oncology #Neoantigens #Clonals

Our CEO Iraj Ali shares his insights with the BioIndustry Association (BIA) Association Community about the recent strides made in oncology research and what the future could hold. He is inspired by the dedication and innovation of researchers in the UK and worldwide working to develop more effective and targeted therapies. At Achilles Therapeutics plc we are using our AI-driven technology to identify target clonal neoantigens for new therapeutic treatments and vaccines for cancer patients. Read the full article here: https://lnkd.in/dT4xmbss #ThoughtLeadership #Oncology #Precision #CancerResearch #Neoantigens #Clonals

June marks LGBTQ Pride Month. For Achilles Therapeutics plc this month is an opportunity to reflect on our commitment to diversity and inclusion. These values are integral to our corporate culture and vital for driving innovation through a variety of perspectives and experiences. To mark #PrideMonth, we are again supporting organizations including the Elton John AIDS Foundation. To find out more about these charities and how you can donate to their cause, visit https://lnkd.in/dnwdSS5 #Oncology #Neoantigens #Clonals

Delighted to be part of this exciting collaboration, funded by EU Horizon: Genesis: A modular protein language modelling approach to immunogenicity prediction https://lnkd.in/gh3daNei

Really happy to share a link to our most recent preprint: https://lnkd.in/enDQ42fp   In it we describe the development of a state-of-the-art immunogenicity predictor, laying the necessary foundation for the DECOD-Ag program. Great collaboration with Marc Mansour, Yardena Samuels, Charles Swanton, Sine Reker Hadrup, UCL Cancer Institute, and Achilles Therapeutics plc, funded by #EUHorizon2020 (EU Science, Research and Innovation).

Today we unveiled a new collaboration with Arcturus Therapeutics, a late clinical-stage messenger RNA medicines company. The collaboration will combine Achilles Therapeutics plc’s best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading sa-mRNA platform to develop self-amplifying personalized mRNA cancer vaccines targeting clonal neoantigens. To read the full press release visit: https://lnkd.in/eTWZ6MQ9 #Collaboration #Oncology #Precision #CancerResearch #Neoantigens #Clonals

Achilles Therapeutics plc’s CSO Sergio Quezada was recently interviewed at the Immuno-Oncology 360° Summit in Boston. Sergio discussed how research into clonal neoantigens, which are mutations present on all tumor cells, opened up an important avenue for precision cell therapies. At Achilles Therapeutics plc, we are developing a next-generation targeted TIL therapy, using our cutting-edge, proprietary bioinformatics platform (PELEUS™) which has the unique ability to define the best neoantigens. To watch the full interview visit: https://lnkd.in/e4xddvRv  #IO360 #Conference #Oncology #Precision #CancerResearch #Neoantigens #Clonals